12:00 AM
 | 
Jan 02, 2012
 |  BC Week In Review  |  Company News  |  Deals

Alexion, Enobia deal

Alexion will acquire bone disease company Enobia for $610 million up front and up to $470 million in milestones. Alexion will gain ENB-0040, a fusion protein of the catalytic domain of human ...

Read the full 155 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >